SRTS Q1 2025: Losses narrow; management sees profit from Q2 onward
- Path to Profitability: Management expects each subsequent quarter to be profitable, which signals a turnaround from the Q1 loss and supports a bullish outlook for sustainable growth ** **.
- Robust Fair Deal Agreement Growth: The significant increase in patient treatments (65% growth) tied to FDA arrangements, coupled with strategic marketing support, indicates that recurring revenue from these agreements could accelerate in the second half of the year ** **.
- Expanding Multisite Pipeline: The progress with large multisite FDA agreements—targeting groups with 10–20 practices—suggests ample room for revenue expansion as these sites ramp up their patient volumes ** **.
- Q1 Revenue Decline & Net Loss: Q1 2025 revenue fell to $8.3 million, down from $10.7 million in Q1 2024, resulting in a net loss of $2.6 million; this decline and loss raise concerns about near-term financial performance.
- High Operating & One-Time Expenses: Elevated marketing, legal, and R&D costs impacted profitability in Q1, suggesting that the company’s aggressive spending may continue to pressure margins until future revenue drivers materialize.
- Reliance on Fair Deal Agreement Ramp-Up: A substantial portion of future revenue is expected from Fair Deal Agreements—which have a 4- to 5-month delay between agreement signing and initial revenue—introducing execution risk if installations or patient volume adoption does not ramp up as anticipated.
| Metric | YoY Change | Reason |
|---|---|---|
Total Revenue | –21.8% (from 10,663K to 8,344K USD) | The 21.8% drop in total revenue is notable when compared to Q1 2024, suggesting that the company experienced significantly lower sales in Q1 2025. Given that revenue in Q1 2024 was higher partly due to strong U.S. market performance, the current decline may indicate challenges in sustaining prior sales momentum, potentially due to adverse market conditions for their large customer base. |
Net Income | Reversal from +2,274K to –2,572K USD | The swing from a positive net income of 2,274K USD in Q1 2024 to a loss of 2,572K USD in Q1 2025 reflects increasing operational challenges. This reversal suggests that the revenue decline was not matched by proportional cost reductions, thereby eroding margins and reversing profitability seen in the prior period. |
Cash and Cash Equivalents | +30% increase (from 14,728K to 19,072K USD) | A nearly 30% increase in cash and cash equivalents indicates improved liquidity despite operational setbacks. This growth might be attributed to effective cash management strategies or lower capital outlays in Q1 2025 relative to Q1 2024, highlighting a shift in financial management compared to the previous period. |
Inventories | –32% decrease (from 14,720K to 9,923K USD) | Inventories dropped by approximately 32% as the company likely adjusted stock levels to align with reduced sales expectations. This reduction contrasts with the higher inventory levels in Q1 2024 and suggests a strategic move to lower holding costs amid a more challenging market environment. |
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Revenue | Q2 2025 | no prior guidance | Expected to exceed Q1 2025 revenue of $8.3M | no prior guidance |
General and Administrative Expenses | Per quarter | no prior guidance | About $1.8 million per quarter | no prior guidance |
Selling and Marketing Expenses | Per quarter | no prior guidance | About $1.3 million per quarter | no prior guidance |
Research and Development Expenses | Per quarter | no prior guidance | About $1.5 million per quarter | no prior guidance |
FDA Program Contributions | FY 2025 | Expected to begin contributing meaningfully in H2 2025 | Anticipated significant revenue contributions starting in the second half of 2025 | no change |
Profitability | FY 2025 | Emphasis on driving sustainable profitable growth | Return to profitability expected in each of the next three quarters and for FY 2025 | raised |
SRT Systems Installations | FY 2025 | no prior guidance | On track to surpass 900 systems by the end of Q2 and reach 1,000 units under direct sale within 12 months | no prior guidance |
International Strategy (Exhibitions) | FY 2025 | no prior guidance | Plans to exhibit at the Australian Academy of Dermatology Annual Meeting | no prior guidance |
TDI FDA Review Cycle | FY 2025 | no prior guidance | FDA review determination expected before year-end following the resubmission in early March | no prior guidance |
| Metric | Period | Guidance | Actual | Performance |
|---|---|---|---|---|
Revenue | Q1 2025 | "Q1 2025 sales to be considerably lower than Q1 2024" | "8.344M USD (vs. 10.663M USD in Q1 2024)" | Met |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Fair Deal Agreement Opportunities and Revenue Recognition Delays | Consistently described in Q2–Q4 2024 and Q3 2024 as a key growth driver with strong adoption among large dermatology groups, clear competitive differentiation, and a set revenue delay timeline (approximately 3–5 months) | In Q1 2025, the FDA is again highlighted for its compelling competitive proposition with rapid adoption and anticipated revenue contributions starting in the second half of the year, while the inherent delay from signing to revenue remains | Consistent positive sentiment; the opportunity remains attractive despite predictable delays in revenue recognition. |
Path to Profitability and Turnaround Strategy | Q2 2024, Q3 2024, and Q4 2024 emphasized strong revenue growth, positive EBITDA, and instances of profitability (with Q4 2024 marking the fifth consecutive profitable quarter) alongside effective cost management | Q1 2025 outlines strategic investments aimed at returning to profitability in the upcoming quarters and for the full year, expecting an improvement despite a current net loss, leveraging the FDA program and cost stabilization | Increasing focus on long-term profitability; short-term results are mixed but strategic investments are expected to drive a turnaround. |
Multisite Pipeline Expansion: Opportunities and Execution Challenges | In Q3 2024, the Platinum Dermatology agreement (covering 130 sites) and discussions with similar large practices were detailed, and Q4 2024 reinforced opportunities via the FDA program for large corporate accounts, although execution challenges such as staggered installations were noted. Q2 2024 did not mention this topic. | Q1 2025 revisits multisite expansion by targeting 3 to 5 additional multisite FDA customers, while reiterating execution challenges due to the 4–5 month installation and revenue delay timeline | Emerging consistency; a sustained focus on expanding multisite agreements with operational execution challenges that remain to be managed. |
Customer Concentration Risk | Q3 2024 highlighted that the largest customer's deals accounted for about 50% of placements, and Q4 2024 mentioned that 25 of 39 units were delivered to their biggest customer. Q2 2024 did not address this issue. | Q1 2025 does not include any specific discussion on customer concentration risk [document not providing details] | Decreased focus; the risk was emphasized in previous quarters but is not discussed in the most recent period, suggesting a possible shift in strategic emphasis. |
Short-Term Financial Performance and Liquidity Challenges | Q2, Q3, and Q4 2024 demonstrated strong revenue growth, improved gross margins, consistent profitability or positive EBITDA, and robust liquidity with healthy cash balances and no debt | Q1 2025 reported a decline in revenue and a net loss, with short-term financial performance suffering due partly to lower sales to the largest customer, yet liquidity remains strong with significant cash reserves and inventory readiness | Mixed sentiment; while liquidity is robust, short-term operational performance shows challenges that management expects to reverse in coming quarters. |
TDI Product Launch Delays and FDA Regulatory Hurdles | Q2 2024 noted delays due to an FDA backlog and described plans to incorporate additional features leading to a resubmission expected in Q3; Q3 2024 mentioned an expected 510(k) submission by year end; Q4 2024 planned for a resubmission in the first half of 2025 | Q1 2025 reported that the TDI 510(k) was resubmitted in early March and noted an absence of follow-up questions from the FDA, suggesting a positive regulatory outlook despite initial delays | Improved sentiment; the progression from delays to a promising submission with no additional queries indicates steady momentum toward market approval. |
International Expansion and Global Market Penetration | Q2 2024 detailed active market entries in Ireland, Guatemala, Turkey, and Asia (Taiwan and China) with further distributor engagements; Q3 2024 described targeted expansions in Asia, the Middle East, and the veterinary market; Q4 2024 highlighted international system shipments and steps toward broader distribution | In Q1 2025, the focus remains on international market penetration, with participation in global events like the ESTRO show in Vienna and upcoming exhibitions in Australia, reinforcing the global strategy | Consistent expansion; international efforts continue steadily with proactive event participation and market penetration strategies. |
Production Capacity and Inventory Readiness | Q2 2024 and Q3 2024 showcased ample inventory buildup, proactive ordering, and assurance of meeting customer demand for direct sales and FDA placements; Q4 2024 emphasized the availability of over 50 paid-for units ready for deployment | Q1 2025 indicated a solid inventory of $9.9 million with plans to order additional units by year-end, affirming confidence in production capacity and readiness to meet market demand | Stable and positive; capacity and inventory management remain robust, ensuring that anticipated demand can be met with proactive production planning. |
-
Quarter Outlook
Q: Will future quarters beat Q1 ’25?
A: Management expects each subsequent quarter to be profitable with improved revenue driven by new initiatives, despite a softer Q1 compared to Q1 ’24. -
Fair Deal Revenue
Q: Was Fair Deal revenue significant in Q1?
A: A portion of Q1 revenue came from Fair Deal Agreements, although it wasn’t large; significant contributions are expected in H2. -
Treatment Growth
Q: What’s behind the 65% treatments growth?
A: Approximately 60% of the 65% growth was organic, with an additional 5% from new go-lives, underlining strong performance in patient treatments. -
Volume Ramp
Q: Does patient volume ramp occur gradually?
A: Yes, once installed and marketing ramps up, patient volumes incrementally build, reflecting a gradual but strong revenue multiplier effect. -
FDA Timeline
Q: How long to generate revenue post-agreement?
A: It takes about 4–5 months from the agreement signing to revenue realization as patient treatments begin to drive income. -
Multisite Opportunity
Q: Are larger groups expanding FDA deals?
A: Larger PE-backed groups are targeting 3–5 additional multisite agreements, tapping into extensive networks for higher-volume installations. -
Regulatory Update
Q: Is the TDI 510(k) submission at risk?
A: The company is confident in its TDI 510(k) resubmission, having received no FDA follow-up questions, and expects a favorable outcome by year-end. -
Installed Base Guidance
Q: What are current and target installed base numbers?
A: Management did not provide specific guidance on the installed base or target numbers, emphasizing a focus on strategic installations instead. -
Tariff Impact
Q: Have U.S. tariffs affected the business?
A: There have been no observable tariff repercussions impacting operations or revenue. -
Payment Timing
Q: When is revenue collected post-treatment?
A: Revenue from treatments is collected between 45 and 60 days after services are rendered, though timing may vary. -
Clinic Utilization
Q: How will clinics reach mature utilization?
A: The company is leveraging data analytics and targeted digital marketing to boost patient engagement at clinics. -
Sales Expense
Q: Does sales expense cover FDA marketing?
A: Yes, the reported sales and marketing expenses include efforts geared toward targeting FDA agreement marketing. -
Conference Profile
Q: Who attends the smaller conferences?
A: They attract regional practitioners and local high-volume centers, offering intimate settings to engage potential multisite partners. -
Multisite Installations
Q: How many units per multisite agreement initially?
A: Larger groups typically start with 10–20 key installations at their highest-volume practices before expanding further. -
Data Alignment
Q: Do clinic choices match patient data?
A: Strong alignment exists as analytics confirm that selected clinics are indeed in high-volume areas, reinforcing installation decisions.
Research analysts covering Sensus Healthcare.